Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Activated cGAS/STING signaling elicits endothelial cell senescence in early diabetic retinopathy.
Liu H, Ghosh S, Vaidya T, Bammidi S, Huang C, Shang P, Nair AP, Chowdhury O, Stepicheva NA, Strizhakova A, Hose S, Mitrousis N, Gadde SG, Mb T, Strassburger P, Widmer G, Lad EM, Fort PE, Sahel JA, Zigler JS Jr, Sethu S, Westenskow PD, Proia AD, Sodhi A, Ghosh A, Feenstra D, Sinha D. Liu H, et al. Among authors: strassburger p. JCI Insight. 2023 Jun 22;8(12):e168945. doi: 10.1172/jci.insight.168945. JCI Insight. 2023. PMID: 37345657 Free PMC article.
Inducers of the endothelial cell barrier identified through chemogenomic screening in genome-edited hPSC-endothelial cells.
Roudnicky F, Zhang JD, Kim BK, Pandya NJ, Lan Y, Sach-Peltason L, Ragelle H, Strassburger P, Gruener S, Lazendic M, Uhles S, Revelant F, Eidam O, Sturm G, Kueppers V, Christensen K, Goldstein LD, Tzouros M, Banfai B, Modrusan Z, Graf M, Patsch C, Burcin M, Meyer CA, Westenskow PD, Cowan CA. Roudnicky F, et al. Among authors: strassburger p. Proc Natl Acad Sci U S A. 2020 Aug 18;117(33):19854-19865. doi: 10.1073/pnas.1911532117. Epub 2020 Aug 5. Proc Natl Acad Sci U S A. 2020. PMID: 32759214 Free PMC article.
Modelling Macular Edema: The Effect of IL-6 and IL-6R Blockade on Human Blood-Retinal Barrier Integrity In Vitro.
Mesquida M, Drawnel F, Lait PJ, Copland DA, Stimpson ML, Llorenç V, Sainz de la Maza M, Adan A, Widmer G, Strassburger P, Fauser S, Dick AD, Lee RWJ, Molins B. Mesquida M, et al. Among authors: strassburger p. Transl Vis Sci Technol. 2019 Oct 28;8(5):32. doi: 10.1167/tvst.8.5.32. eCollection 2019 Sep. Transl Vis Sci Technol. 2019. PMID: 31667008 Free PMC article.
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.
Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G. Regula JT, et al. Among authors: strassburger p. EMBO Mol Med. 2016 Nov 2;8(11):1265-1288. doi: 10.15252/emmm.201505889. Print 2016 Nov. EMBO Mol Med. 2016. PMID: 27742718 Free PMC article.
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.
Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Chui Ming GC, Tun SBB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G. Regula JT, et al. Among authors: strassburger p. EMBO Mol Med. 2019 May;11(5):e10666. doi: 10.15252/emmm.201910666. EMBO Mol Med. 2019. PMID: 31040127 Free PMC article.
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.
Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Gemmy Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G. Regula JT, et al. Among authors: strassburger p. EMBO Mol Med. 2017 Jul;9(7):985. doi: 10.15252/emmm.201707895. EMBO Mol Med. 2017. PMID: 28533211 Free PMC article.
Efficacy of combining intravitreal injections of ranibizumab with micropulse diode laser versus intravitreal injections of ranibizumab alone in diabetic macular edema (ReCaLL): a single center, randomised, controlled, non-inferiority clinical trial.
Furashova O, Strassburger P, Becker KA, Engelmann K. Furashova O, et al. Among authors: strassburger p. BMC Ophthalmol. 2020 Jul 29;20(1):308. doi: 10.1186/s12886-020-01576-w. BMC Ophthalmol. 2020. PMID: 32727496 Free PMC article. Clinical Trial.
20 results